Company Profile

Genetic Systems Corporation (AKA: GSC)
Profile last edited on: 10/31/22      CAGE: 0D6X2      UEI:

Business Identifier: Monoclonal antibodies
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

6565 185th Avenue NorthEast
Redmond, WA 98052
   (206) 624-4300
Location: Single
Congr. District: 01
County: King

Public Profile

Genetic Systems Corporation (GSC), a Seattle-based biotechnology company. was founded by a group of entrepreneurial microbiologists who teamed up with Syntex Corporation, a drug company, to manufacture and market tests for sexually transmitted diseases. The entitiy was organized around commercializing monoclonal antibody technology - a totally new technology at the time. Three years later, the partners formed another venture, Oncogen, to manufacture products for cancer treatment, and in 1985, Bristol-Myers was offered an opportunity to invest in the operation. A very young - but already leading-edge Genetic Systems Corporation was originally acquired for about $300M by Bristol Myers Squibb in Fall 1985 along the biotech firm's holding in the Oncogen joint venture with Syntex. In 1990 - for an undislosed sum - BMS sold to Sanofi the diagnostics portion of Genetic Systems. The young firm's leading product was an in vitro test for AIDS. It was suggested at the time that Genetic System would give Sanofi a much-desired foothold in the U.S. on which to build a U.S. presence. In the meantime, Bristol-Myers Squibb had set up Oncogen as an internal research subsidiary and spliced into it "all non-diagnostic research activities that were part of Genetic Systems." A Bristol-Myers Squibb press release notes that Oncogen "would remain an important part of the newly restructured Bristol-Myers Squibb Pharmaceutical Research Institute." Founded in 1980, The company was taken public in 1983

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1984 1 NIH $50,000
Project Title: Detection of Antibiotic-Resistance in Bacteria
1983 1 NIH $50,000
Project Title: Rapid Methods to Monitor Genetic Damage in Humans
1983 1 NIH $50,000
Project Title: New Method to Detect Immune Complexes
1983 1 NIH $50,000
Project Title: Diagnostic tests for atherosclerosis

Key People / Management

  Isaac Bletch -- Founder

  Edward Clark

  Paul Gladstone

  Lynn Goldstein

  Robert Nowinski -- Founder

  Milton R Tam